74550-97-3

• 常用中文名：AT-1727
• 常用英文名：AT-1727
• CAS号：74550-97-3
• 分子式：C₂₀H₃₂N₆O₆
• 分子量：452.50
• 相关类别： 信号通路 细胞周期/DNA损伤 拓扑异构酶
• 发布时间：2016-10-15 18:08:13
• 更新时间：2024-01-08 21:08:07
• 双吗啉(AT-1727)是一种人类拓扑异构酶II抑制剂,可以用作抗肿瘤药物和银屑病的研究。双吗啉显示出白血病活性,并在人类淋巴细胞中诱导多种类型的染色体畸变[1][2]。

名称

• 英文名: 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]ethyl]piperazine-2,6-dione
• 英文别名: AT-1727; Bimolane; 1,2-Bis(4-morpholinomethyl-3,5-dixoxpiperazinyl)ethane; 2,6-Piperazinedione,4,4'-ethylenebis(1-(morpholinomethyl); 1,2-Bis(4-morpholinomethyl-3,5-dioxopiperazinyl)-ethane; 4,4'-ethane-1,2-diylbis[1-(morpholin-4-ylmethyl)piperazine-2,6-dione]

物化性质

• 密度: 1.326g/cm3
• 沸点: 679.2ºC at 760 mmHg
• 分子式: C₂₀H₃₂N₆O₆
• 分子量: 452.50
• 闪点: 364.6ºC
• 精确质量: 452.23800
• PSA: 106.18000
• 折射率: 1.568

生物活性

• 描述: 双吗啉(AT-1727)是一种人类拓扑异构酶II抑制剂,可以用作抗肿瘤药物和银屑病的研究。双吗啉显示出白血病活性,并在人类淋巴细胞中诱导多种类型的染色体畸变[1][2]。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> 细胞周期/DNA损伤 >> 拓扑异构酶
• 靶点:

  Topoisomerase II

• 参考文献:

  [1]. Frantz CE, et, al. Bimolane: in vitro inhibitor of human topoisomerase II. Cancer Lett. 1997 Dec 9;120(2):135-40.

  [2]. Roy SK, et, al. Bimolane induces multiple types of chromosomal aberrations in human lymphocytes in vitro. Mutat Res. 2011 Dec 24;726(2):181-7.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : TL6380300 CHEMICAL NAME : 2,6-Piperazinedione, 4,4'-ethylenebis(1-(morpholinomethyl)- CAS REGISTRY NUMBER : 74550-97-3 LAST UPDATED : 199612 DATA ITEMS CITED : 12 MOLECULAR FORMULA : C20-H32-N6-O6 MOLECULAR WEIGHT : 452.58 WISWESSER LINE NOTATION : T6VNV ENTJ B1- AT6N DOTJ& E2- ET6VNV ENTJ B1- AT6N DOTJ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 280 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 250 mg/kg/10D-I TOXIC EFFECTS : Behavioral - food intake (animal) Blood - changes in leukocyte (WBC) count TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 140 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1400 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - homeostasis TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 280 mg/kg SEX/DURATION : female 10 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 37 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 149 mg/kg SEX/DURATION : female 6-15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 37200 ug/kg SEX/DURATION : female 10 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 9 mg/kg SEX/DURATION : female 7-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death MUTATION DATA TEST SYSTEM : Rodent - mouse DOSE/DURATION : 5 mg/kg REFERENCE : CYLPDN Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1980- Volume(issue)/page/year: 16,531,1995